التفاصيل البيبلوغرافية
| العنوان: |
Pregabalin in the treatment of post-traumatic peripheral neuropathic pain: a randomized double-blind trial. |
| المؤلفون: |
van Seventer, R., Bach, F. W., Toth, C. C., Serpell, M., Temple, J., Murphy, T. K., Nimour, M. |
| المصدر: |
European Journal of Neurology; Aug2010, Vol. 17 Issue 8, p1082-1089, 8p, 3 Charts, 2 Graphs |
| مصطلحات موضوعية: |
PLACEBOS, NEUROLOGIC manifestations of general diseases, PAIN, PATIENTS, MENTAL depression |
| مستخلص: |
Background: Pregabalin is effective in the treatment of peripheral and central neuropathic pain. This study evaluated pregabalin in the treatment of post-traumatic peripheral neuropathic pain (including post-surgical). Methods: Patients with a pain score ≥4 (0–10 scale) were randomized and treated with either flexible-dose pregabalin 150–600 mg/day ( n = 127) or placebo ( n = 127) in an 8-week double-blind treatment period preceded by a 2-week placebo run-in. Results: Pregabalin was associated with a significantly greater improvement in the mean end-point pain score vs. placebo; mean treatment difference was −0.62 (95% CI −1.09 to −0.15) ( P = 0.01). The average pregabalin dose at end-point was ∼326 mg/day. Pregabalin was also associated with significant improvements from baseline in pain-related sleep interference, and the Medical Outcomes Study sleep scale sleep problems index and sleep disturbance subscale (all P < 0.001). In the all-patient group (ITT), pregabalin was associated with a statistically significant improvement in the Hospital Anxiety and Depression Scale anxiety subscale ( P < 0.05). In total, 29% of patients had moderate/severe baseline anxiety; treatment with pregabalin in this subset did not significantly improve anxiety. More patients reported global improvement at end-point with pregabalin than with placebo (68% vs. 43%; overall P < 0.01). Adverse events led to discontinuation of 20% of patients from pregabalin and 7% from placebo. Mild or moderate dizziness and somnolence were the most common adverse events in the pregabalin group. Conclusion: Flexible-dose pregabalin 150–600 mg/day was effective in relieving neuropathic pain, improving disturbed sleep, improving overall patient status, and was generally well tolerated in patients with post-traumatic peripheral neuropathic pain. [ABSTRACT FROM AUTHOR] |
|
Copyright of European Journal of Neurology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder